These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

329 related items for PubMed ID: 24385259

  • 1. Systematic assessment of decision-analytic models for chronic myeloid leukemia.
    Rochau U, Schwarzer R, Jahn B, Sroczynski G, Kluibenschaedl M, Wolf D, Radich J, Brixner D, Gastl G, Siebert U.
    Appl Health Econ Health Policy; 2014 Apr; 12(2):103-15. PubMed ID: 24385259
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Economic Evaluations of Tyrosine Kinase Inhibitors for Patients with Chronic Myeloid Leukemia in Middle- and High-Income Countries: A Systematic Review.
    Fu J, Liu Y, Lin H, Wu B.
    Clin Drug Investig; 2018 Dec; 38(12):1167-1178. PubMed ID: 30232698
    [Abstract] [Full Text] [Related]

  • 4. Cost-efficacy of imatinib versus allogeneic bone marrow transplantation with a matched unrelated donor in the treatment of chronic myelogenous leukemia: a decision-analytic approach.
    Skrepnek GH, Ballard EE.
    Pharmacotherapy; 2005 Mar; 25(3):325-34. PubMed ID: 15843279
    [Abstract] [Full Text] [Related]

  • 5. Medical decision analysis for first-line therapy of chronic myeloid leukemia.
    Rochau U, Sroczynski G, Wolf D, Schmidt S, Conrads-Frank A, Jahn B, Saverno K, Brixner D, Radich J, Gastl G, Siebert U.
    Leuk Lymphoma; 2014 Aug; 55(8):1758-67. PubMed ID: 24160847
    [Abstract] [Full Text] [Related]

  • 6. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL, Comeau JM.
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of dasatinib versus high-dose imatinib in patients with Chronic Myeloid Leukemia (CML), resistant to standard dose imatinib--a Swedish model application.
    Ghatnekar O, Hjalte F, Taylor M.
    Acta Oncol; 2010 Aug; 49(6):851-8. PubMed ID: 20615173
    [Abstract] [Full Text] [Related]

  • 8. Cost-effectiveness of Tyrosine Kinase Inhibitor Treatment Strategies for Chronic Myeloid Leukemia in Chronic Phase After Generic Entry of Imatinib in the United States.
    Padula WV, Larson RA, Dusetzina SB, Apperley JF, Hehlmann R, Baccarani M, Eigendorff E, Guilhot J, Guilhot F, Hehlmann R, Mahon FX, Martinelli G, Mayer J, Müller MC, Niederwieser D, Saussele S, Schiffer CA, Silver RT, Simonsson B, Conti RM.
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26944912
    [Abstract] [Full Text] [Related]

  • 9. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M.
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [Abstract] [Full Text] [Related]

  • 10. Cost-effectiveness of interferon alfa in chronic myelogenous leukemia.
    Liberato NL, Quaglini S, Barosi G.
    J Clin Oncol; 1997 Jul; 15(7):2673-82. PubMed ID: 9215840
    [Abstract] [Full Text] [Related]

  • 11. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
    Román J, Alvarez MA, Torres A.
    Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
    [Abstract] [Full Text] [Related]

  • 12. Cost-utility analysis of imatinib mesylate for the treatment of chronic myelogenous leukemia in the chronic phase.
    Warren E, Ward S, Gordois A, Scuffham P.
    Clin Ther; 2004 Nov; 26(11):1924-33. PubMed ID: 15639704
    [Abstract] [Full Text] [Related]

  • 13. Unrelated donor bone marrow transplantation for chronic myelogenous leukemia: a decision analysis.
    Lee SJ, Kuntz KM, Horowitz MM, McGlave PB, Goldman JM, Sobocinski KA, Hegland J, Kollman C, Parsons SK, Weinstein MC, Weeks JC, Antin JH.
    Ann Intern Med; 1997 Dec 15; 127(12):1080-8. PubMed ID: 9412310
    [Abstract] [Full Text] [Related]

  • 14. Decision-Analytic Modeling Studies in Prevention and Treatment of Iodine Deficiency and Thyroid Disorders: A Systematic Overview.
    Rochau U, Qerimi Rushaj V, Schaffner M, Schönhensch M, Stojkov I, Jahn B, Hubalewska-Dydejczyk A, Erlund I, Thuesen BH, Zimmermann M, Moreno-Reyes R, Lazarus JH, Völzke H, Siebert U.
    Thyroid; 2020 May 15; 30(5):746-758. PubMed ID: 31964247
    [Abstract] [Full Text] [Related]

  • 15. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L, Hughes TE, Walsh-Chocolaad TL.
    Ann Pharmacother; 2013 Dec 15; 47(12):1703-11. PubMed ID: 24396109
    [Abstract] [Full Text] [Related]

  • 16. Systematic assessment of decision models in Parkinson's disease.
    Siebert U, Bornschein B, Walbert T, Dodel RC.
    Value Health; 2004 Dec 15; 7(5):610-26. PubMed ID: 15367256
    [Abstract] [Full Text] [Related]

  • 17. Decision-analytic modeling studies: An overview for clinicians using multiple myeloma as an example.
    Rochau U, Jahn B, Qerimi V, Burger EA, Kurzthaler C, Kluibenschaedl M, Willenbacher E, Gastl G, Willenbacher W, Siebert U.
    Crit Rev Oncol Hematol; 2015 May 15; 94(2):164-78. PubMed ID: 25620327
    [Abstract] [Full Text] [Related]

  • 18. Cost-effectiveness of interferon-alpha and conventional chemotherapy in chronic myelogenous leukemia.
    Kattan MW, Inoue Y, Giles FJ, Talpaz M, Ozer H, Guilhot F, Zuffa E, Huber SL, Beck JR.
    Ann Intern Med; 1996 Oct 01; 125(7):541-8. PubMed ID: 8815752
    [Abstract] [Full Text] [Related]

  • 19. Systematic Review of Modelling Approaches for the Cost Effectiveness of Hepatitis C Treatment with Direct-Acting Antivirals.
    Chhatwal J, He T, Lopez-Olivo MA.
    Pharmacoeconomics; 2016 Jun 01; 34(6):551-67. PubMed ID: 26748919
    [Abstract] [Full Text] [Related]

  • 20. Cost sharing and adherence to tyrosine kinase inhibitors for patients with chronic myeloid leukemia.
    Dusetzina SB, Winn AN, Abel GA, Huskamp HA, Keating NL.
    J Clin Oncol; 2014 Feb 01; 32(4):306-11. PubMed ID: 24366936
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.